Knockdown of apolipoprotein B, an atherogenic apolipoprotein, in HepG2 cells by lentivirus-mediated siRNA

Biochemical and Biophysical Research Communications

Volumn 344, Issue 2, 2006, Pages 478-483

  Liao, Wei ^a,b   Ning, Guang ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

apoB; Atherosclerosis; HepG2 cells; Lentivirus; Lipoproteins; siRNA

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; I KAPPA B KINASE ALPHA; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL STRAIN HEPG2; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME PHOSPHORYLATION; GENE CONSTRUCT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; INSULIN RESPONSE; KNOCKOUT GENE; LENTIVIRINAE; LIPOPROTEIN DEFICIENCY; LIPOPROTEIN SECRETION; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; SEQUENCE HOMOLOGY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

APOLIPOPROTEINS B; ATHEROSCLEROSIS; CELL LINE; GENE SILENCING; GENE TARGETING; GENE THERAPY; HEPATOCYTES; HUMANS; LENTIVIRUS; RNA, SMALL INTERFERING; TRANSFECTION;

LENTIVIRUS;

EID: 33646097693     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.164     Document Type: Article

References (40)

1. Kane J.P., and Havel R.J. Disorder of the biogenesis and secretion of lipoprotein containing the B apolipoproteins. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease (1995), McGraw-Hill, New York 1853-1885
2. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J. Biol. Chem. 267 (1992) 25621-25624
3. Anderson K.M., Castelli W.P., and Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. J. Am. Med. Assoc. 257 (1987) 2176-2180
4. Steinberg D., Carew T.E., Fielding C., Fogelman A.M., Mahley R.W., Sniderman A.D., and Zilversmit D.B. Lipoproteins and the pathogenesis of atherosclerosis. Circulation 80 (1989) 719-723
5. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., and Lusis A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91 (1995) 2488-2496
6. Wetterau J.R., Gregg R.E., Harrity T.W., Arbeeny C., Cap M., Connolly F., Chu C.H., George R.J., Gordon D.A., Jamil H., Jolibois K.G., Kunselman L.K., Lan S.J., Maccagnan T.J., Ricci B., Yan M., Young D., Chen Y., Fryszman O.M., Logan J.V., Musial C.L., Poss M.A., Robl J.A., Simpkins L.M., Biller S.A., et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 282 (1998) 751-754
7. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Rohl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., and Vornlocher H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004) 173-178
8. Chang G., Ruggeri R.B., and Harwood H.J. Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curr. Opin. Drug Discov. Dev. 5 (2002) 562-570
9. Berriot-Varoqueaux N., Aggerbeck L.P., Samson-Bouma M., and Wetterau J.R. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu. Rev. Nutr. 20 (2000) 663-697
10. Hussain M.M., Shi J., and Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res. 44 (2003) 22-32
11. Wetterau J.R., and Zilversmit D.B. A triglyceride and cholesteryl ester transfer protein associated with liver microsomes. J. Biol. Chem. 259 (1984) 10863-10866
12. Jamil H., Gordon D.A., Eustice D.C., Brooks C.M., Dickson Jr. J.K., Chen Y., Ricci B., Chu C.H., Harrity T.W., Ciosek Jr. C.P., Biller S.A., Gregg R.E., and Wetterau J.R. An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc. Natl. Acad. Sci. USA 93 (1996) 11991-11995
13. Haghpassand M., Wilder D., and Moberly J.B. Inhibition of apolipoprotein B and triglyceride secretion in human hepatoma cells (HepG2). J. Lipid Res. 37 (1996) 1468-1480
14. Ksander G.M., deJesus R., Yuan A., Fink C., Moskal M., Carlson E., Kukkola P., Bilci N., Wallace E., Neubert A., Feldman D., Mogelesky T., Poirier K., Jeune M., Steele R., Wasvery J., Stephan Z., Cahill E., Webb R., Navarrete A., Lee W., Gibson J., Alexander N., Sharif H., and Hospattankar A. Diaminoindanes as microsomal triglyceride transfer protein inhibitors. J. Med. Chem. 44 (2001) 4677-4687
15. Liao W., Hui T.Y., Young S.G., and Davis R.A. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J. Lipid Res. 44 (2003) 978-985
16. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270 (2003) 1628-1644
17. Elbashir S.M., Harborth J., Weber K., and Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26 (2002) 199-213
18. Hannon G.J., and Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature 431 (2004) 371-378
19. Nencioni A., Sandy P., Dillon C., Kissler S., Blume-Jensen P., and Van Parijs L. RNA interference for the identification of disease-associated genes. Curr. Opin. Mol. Ther. 6 (2004) 136-140
20. Dashti N., and Wolfbauer G. Secretion of lipids, apolipoproteins, and lipoproteins by human hepatoma cell line, HepG2: effects of oleic acid and insulin. J. Lipid Res. 28 (1987) 423-436
21. Liao W., Kobayashi K., and Chan L. Adenovirus-mediated overexpression of microsomal triglyceride transfer protein (MTP): mechanistic studies on the role of MTP in apolipoprotein B-100 biogenesis. Biochemistry 38 (1999) 7532-7544
22. Rubinson D.A., Dillon C.P., Kwiatkowski A.V., Sievers C., Yang L., Kopinja J., Rooney D.L., Ihrig M.M., McManus M.T., Gertler F.B., Scott M.L., and Van Parijs L. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 33 (2003) 401-406
23. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
24. Miyagishi M., Sumimoto H., Miyoshi H., Kawakami Y., and Taira K. Optimization of an siRNA-expression system with an improved hairpin and its significant suppressive effects in mammalian cells. J. Gene Med. 6 (2004) 715-723
25. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
26. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., and Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72 (1998) 8463-8471
27. Pfeifer A., Kessler T., Silletti S., Cheresh D.A., and Verma I.M. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl. Acad. Sci. USA 97 (2000) 12227-12232
28. Naldini L., Blomer U., Gage F.H., Trono D., and Verma I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93 (1996) 11382-11388
29. Liao W., Yeung S.C., and Chan L. Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum. J. Biol. Chem. 273 (1998) 27225-27230
30. Liao W., and Chan L. Apolipoprotein B, a paradigm for proteins regulated by intracellular degradation, does not undergo intracellular degradation in CaCo2 cells. J. Biol. Chem. 275 (2000) 3950-3956
31. Fisher E.A., and Ginsberg H.N. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem. 277 (2002) 17377-17380
32. Chan L., Chang B.H., Liao W., Oka K., and Lau P.P. Apolipoprotein B: from editosome to proteasome. Recent Prog Horm Res 55 (2000) 93-125 discussion 126
33. Liao W., Chang B.H., Mancini M., and Chan L. Ubiquitin-dependent and -independent proteasomal degradation of apoB associated with endoplasmic reticulum and Golgi apparatus, respectively, in HepG2 cells. J. Cell Biochem. 89 (2003) 1019-1029
34. Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2 (2002) 725-734
35. Yamamoto Y., and Gaynor R.B. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem. Sci. 29 (2004) 72-79
36. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001) 807-869
37. Manning A.M., and Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat. Rev. Drug Discov. 2 (2003) 554-565
38. Mitchell R., Chiang C.Y., Berry C., and Bushman F. Global analysis of cellular transcription following infection with an HIV-based vector. Mol. Ther. 8 (2003) 674-687
39. Pan D., Gunther R., Duan W., Wendell S., Kaemmerer W., Kafri T., Verma I.M., and Whitley C.B. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol. Ther. 6 (2002) 19-29
40. Schroder M., and Kaufman R.J. ER stress and the unfolded protein response. Mutat. Res. 569 (2005) 29-63